Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Oxford Immunotec
Thumbnail
April 12, 2021

Diasorin heads to the US with $1.8bn Luminex deal

And consolidation in the diagnostics space is only just beginning.

Thumbnail
March 08, 2021

Adaptive’s Covid-19 T-cell test hits the US

As with antibodies, the next step will be proving that T-cells can grant immunity.

Article image
Vantage logo
January 07, 2021

Oxford Immunotec hits the spot for Perkinelmer

Article image
Vantage logo
November 12, 2020

Qiagen enters the T-cell testing fray

At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.

Article image
Vantage logo
November 10, 2020

First data hint at T-cell immunity to Covid-19

Oxford Immunotec’s test might be able to pinpoint those at low risk of reinfection.

Article image
Vantage logo
October 07, 2020

The other kind of Covid-19 immunity

As antibody tests pile up, Oxford Immunotec is working on an assay to detect T-cell responses to the coronavirus.

Article image
Vantage logo
August 22, 2019

The extremes converge in big medtech’s hiring practices

Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.

Article image
Vantage logo
August 02, 2017

Lack of takeovers sees medtech hiring staff again

Intuitive Surgical is the winner in terms of sales per employee, despite increasing its headcount 17%.

Vantage logo
April 04, 2014

Orthopaedics companies seek to follow diagnostics in going public

Vantage logo
November 18, 2013

CardioDx yanks float as medtech market fails to pick up

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

July 18, 2022

Medtech - Going steady

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.